Abstract
Trypsin activates proteinase-activated receptor-2 (PAR2) by a mechanism that involves the release of a tethered receptor-activating sequence. We have identified two peptides, FSLLRY-NH2(FSY-NH2) and LSIGRL-NH2 (LS-NH2) that block the ability of trypsin to activate PAR2 either in PAR2-expressing Kirsten virus-transformed kidney (KNRK) cell lines or in a rat aorta ring preparation. The reverse PAR2 peptide, LRGILS-NH2 (LRG-NH2) did not do so and FSY-NH2 failed to block thrombin activation of PAR1 in the aorta ring or in PAR1-expressing human embryonic kidney cells. Half-maximal inhibition (IC50) by FSY-NH2 and LS-NH2 of the activation of PAR2 by trypsin in a PAR2 KNRK calcium-signaling assay was observed at about 50 and 200 μM, respectively. In contrast, the activation of PAR2 by the PAR2-activating peptide, SLIGRL-NH2 (SL-NH2) was not inhibited by FSY-NH2, LS-NH2, or LRG-NH2. In a casein proteolysis assay, neither FSY-NH2 nor LS-NH2 inhibited the proteolytic action of trypsin on its substrate. In addition, FSY-NH2 and LS-NH2 were unable to prevent trypsin from hydrolyzing a 20-amino acid peptide, GPNSKGR/SLIGRLDTPYGGC representing the trypsin cleavage/activation site of rat PAR2. Similarly, FSY-NH2 and LS-NH2 failed to block the ability of trypsin to release the PAR2 N-terminal epitope that is cleaved from the receptor upon proteolytic activation of receptor-expressing KNRK cells. We conclude that the peptides FSY-NH2 and LS-NH2 block the ability of trypsin to activate PAR2 by a mechanism that does not involve a simple inhibition of trypsin proteolytic activity, but possibly by interacting with a tethered ligand receptor-docking site.
Footnotes
-
Supported primarily by an operating grant from the Canadian Institutes of Health Research (formerly Medical Research Council of Canada) and by ancillary support from a Kidney Foundation of Canada operating grant (to S.J.W.) and a Johnson & Johnson focused giving grant.
- Abbreviations:
- Amino acids are abbreviated by their one-letter code
- PAR, proteinase-activated receptor
- AP
- activating peptides
- STI
- soya trypsin inhibitor
- B5
- antibody targeted to the cleavage/activation sequence (GPNSKGRSLIGRLDTP) of rat PAR2
- FSY-NH2
- FSLLRY-NH2
- HEK
- human embryonic kidney
- KNRK
- Kirsten virus-transformed rat kidney
- LRG-NH2
- LRGILS-NH2
- LS-NH2
- LSIGRL-NH2
- P20
- GPNSKGRSLIGRLDTPYGGC, peptide representing the PAR2 cleavage/activation site with a C-terminal sequence (YGGC) added for radiolabeling and protein conjugation via cysteine
- PCR
- polymerase chain reaction
- SLAW
- antibody targeted to the N-terminal epitope on PAR2, released by trypsin
- SL-NH2
- SLIGRL-NH2
- Received August 29, 2001.
- Accepted November 2, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|